JP2020532956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532956A5 JP2020532956A5 JP2020507093A JP2020507093A JP2020532956A5 JP 2020532956 A5 JP2020532956 A5 JP 2020532956A5 JP 2020507093 A JP2020507093 A JP 2020507093A JP 2020507093 A JP2020507093 A JP 2020507093A JP 2020532956 A5 JP2020532956 A5 JP 2020532956A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hla
- ebv
- positive
- epstein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170101800 | 2017-08-10 | ||
| KR10-2017-0101800 | 2017-08-10 | ||
| PCT/KR2018/009224 WO2019031938A2 (ko) | 2017-08-10 | 2018-08-10 | 암 치료를 위한 t 세포의 활성화 방법 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532956A JP2020532956A (ja) | 2020-11-19 |
| JP2020532956A5 true JP2020532956A5 (enExample) | 2021-09-09 |
| JP7364237B2 JP7364237B2 (ja) | 2023-10-18 |
Family
ID=65271692
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507093A Active JP7364237B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
| JP2020507103A Active JP7693189B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
| JP2023093867A Withdrawn JP2023113855A (ja) | 2017-08-10 | 2023-06-07 | 癌治療のためのｔ細胞の活性化方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507103A Active JP7693189B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
| JP2023093867A Withdrawn JP2023113855A (ja) | 2017-08-10 | 2023-06-07 | 癌治療のためのｔ細胞の活性化方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11918634B2 (enExample) |
| EP (2) | EP3666888A4 (enExample) |
| JP (3) | JP7364237B2 (enExample) |
| KR (5) | KR102148866B1 (enExample) |
| CN (2) | CN110997903B (enExample) |
| BR (1) | BR112020002816A2 (enExample) |
| WO (2) | WO2019031939A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020162696A1 (ko) * | 2019-02-08 | 2020-08-13 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| WO2020170254A1 (en) * | 2019-02-21 | 2020-08-27 | Ramot At Tel-Aviv University Ltd. | Treatment of diseases with multimeric peptides |
| KR102182555B1 (ko) * | 2019-03-14 | 2020-11-24 | 한국과학기술연구원 | T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼 |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| WO2021061736A1 (en) * | 2019-09-23 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cells |
| KR20210102091A (ko) | 2020-02-11 | 2021-08-19 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| GB202010095D0 (en) * | 2020-07-01 | 2020-08-12 | Tcer Ab | Immunotherapy |
| KR20220118225A (ko) | 2021-02-18 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| KR20220131170A (ko) | 2021-03-19 | 2022-09-27 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| CN114230656B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| CN116731964A (zh) * | 2022-05-26 | 2023-09-12 | 苏州尔生生物医药有限公司 | 用于预防或治疗癌症的特异性t细胞及其制备方法 |
| WO2024151124A1 (ko) * | 2023-01-12 | 2024-07-18 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| WO2025240737A1 (en) * | 2024-05-16 | 2025-11-20 | Rutgers, The State University Of New Jersey | Methods of producing memory t cells in vitro and their use in immunotherapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| AU2003228067B2 (en) | 2002-04-22 | 2008-05-29 | Recopharma Ab | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| GB0214528D0 (en) * | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| ES2390967T3 (es) * | 2004-01-20 | 2012-11-20 | Aichi Prefecture | Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| JP4824389B2 (ja) | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| US20090155275A1 (en) * | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| KR20110036618A (ko) | 2008-07-16 | 2011-04-07 | 베일러 리서치 인스티튜트 | 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신 |
| KR20120059581A (ko) * | 2009-08-24 | 2012-06-08 | 윌슨 울프 매뉴팩처링 | 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성 |
| CN101643497A (zh) * | 2009-09-15 | 2010-02-10 | 南京医科大学 | Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途 |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US9402916B2 (en) * | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | Ｔ細胞を増殖させるプロセス |
| GB201312133D0 (en) | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| US10987412B2 (en) * | 2014-09-17 | 2021-04-27 | The John Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells |
| RU2719033C2 (ru) * | 2015-04-23 | 2020-04-16 | Нантомикс, Ллс | Способ получения фармацевтического агента для иммунотерапии рака |
| CA2986235A1 (en) * | 2015-05-20 | 2016-11-24 | The Broad Institute, Inc. | Shared neoantigens |
| WO2016203577A1 (ja) | 2015-06-17 | 2016-12-22 | 株式会社医学生物学研究所 | 細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| AU2016339924B2 (en) * | 2015-10-12 | 2020-01-02 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| CA3003251A1 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
| KR102883915B1 (ko) * | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| AU2017271128A1 (en) * | 2016-05-25 | 2019-01-03 | The Council Of The Queensland Institute Of Medical Research | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
| SG11201900132QA (en) * | 2016-07-20 | 2019-02-27 | Biontech Rna Pharmaceuticals Gmbh | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
-
2018
- 2018-08-10 KR KR1020180093946A patent/KR102148866B1/ko active Active
- 2018-08-10 EP EP18844804.7A patent/EP3666888A4/en not_active Withdrawn
- 2018-08-10 EP EP18843560.6A patent/EP3666887A4/en not_active Withdrawn
- 2018-08-10 US US16/638,055 patent/US11918634B2/en active Active
- 2018-08-10 WO PCT/KR2018/009225 patent/WO2019031939A2/ko not_active Ceased
- 2018-08-10 CN CN201880052032.2A patent/CN110997903B/zh active Active
- 2018-08-10 KR KR1020180093897A patent/KR102190890B1/ko active Active
- 2018-08-10 BR BR112020002816-9A patent/BR112020002816A2/pt not_active Application Discontinuation
- 2018-08-10 CN CN201880052033.7A patent/CN111433355B/zh active Active
- 2018-08-10 WO PCT/KR2018/009224 patent/WO2019031938A2/ko not_active Ceased
- 2018-08-10 US US16/637,927 patent/US11969463B2/en active Active
- 2018-08-10 JP JP2020507093A patent/JP7364237B2/ja active Active
- 2018-08-10 JP JP2020507103A patent/JP7693189B2/ja active Active
-
2020
- 2020-08-21 KR KR1020200105269A patent/KR20200102402A/ko not_active Withdrawn
- 2020-12-08 KR KR1020200170517A patent/KR20200141424A/ko not_active Ceased
-
2022
- 2022-09-08 KR KR1020220114288A patent/KR20220136957A/ko not_active Ceased
-
2023
- 2023-06-07 JP JP2023093867A patent/JP2023113855A/ja not_active Withdrawn
-
2024
- 2024-01-25 US US18/423,189 patent/US20240156927A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532957A5 (enExample) | ||
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| JP7034955B2 (ja) | 免疫療法向けのｔ細胞組成物 | |
| Goodier et al. | CMV and natural killer cells: shaping the response to vaccination | |
| JP2019519246A5 (enExample) | ||
| Méndez-Samperio | Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease | |
| JP6333730B2 (ja) | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 | |
| JP7078937B2 (ja) | 免疫細胞を操作するための抗原提示足場 | |
| Cayeux et al. | Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation | |
| JP7364237B2 (ja) | 癌治療のためのｔ細胞の活性化方法 | |
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| Wiesel et al. | Type I IFN substitutes for T cell help during viral infections | |
| JP2019507608A5 (enExample) | ||
| Huss et al. | TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| JP2006514057A5 (enExample) | ||
| Akuffo et al. | Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells | |
| Rizza et al. | Cytokines as natural adjuvants for vaccines: where are we now? | |
| Keppler et al. | Signal 3 requirement for memory CD8+ T‐cell activation is determined by the infectious pathogen | |
| JP2024502034A5 (enExample) | ||
| Charo et al. | DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I-and II-restricted T cell responses that can be augmented by cytokines | |
| JP2022519378A (ja) | がん治療のためのｔ細胞の活性化方法 | |
| JP2019536429A5 (enExample) | ||
| Sad et al. | Maintenance and attrition of T-cell memory | |
| JP6871432B2 (ja) | Ｐｌｋ１タンパク質に対する抗原に特異的なｔ細胞の免疫反応を誘導するｈｌａ−ａ２亜型に特異的なｐｌｋ１由来の抗原決定基 |